{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:37:59Z","timestamp":1772800679150,"version":"3.50.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1994,4]]},"abstract":"<jats:p>Vidal-Puig AJ, Mu\u00f1oz-Torres M, J\u00f3dar-Gimeno E, Garc\u00eda-Calvente CJ, Lardelli P, Ruiz-Requena ME, Escobar-Jim\u00e9nez F. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol 1994;130:333\u20138. ISSN 0804\u20134643.<\/jats:p>\n        <jats:p>The aim of this study was to assess the usefulness of ketoconazole as a therapeutic alternative to polycystic ovary syndrome. The study group comprised 37 women with signs of hyperandrogenism (hirsutism, acne) and oligomenorrhea. A low dose (400 mg\/day) of ketoconazole was tested in a 9-month prospective clinical study. Clinical response (Ferriman &amp; Gallway score, acne) and modifications in hormone pattern (luteinizing hormone, follicle-stimulating hormone, estradiol, testosterone, prolactin, 17-hydroxy-progesterone, androstenedione, steroid hormone-binding globulin, dehydroepiandrosterone sulfate, cortisol, adrenocorticotropin (ACTH) and free testosterone index) were measured, and ACTH stimulation tests were performed. Tolerance and side-effects also were assessed. After 9 months of ketoconazole treatment, the patients' Ferriman &amp; Gallway scores (18.26 \u00b1 4.6 vs 12.4 \u00b1 4.1; p &lt; 0.001) and acne had improved markedly. Hormone patterns also became more favorable, with decreases in androgenic steroids (testosterone, androstenedione, free testosterone index and dehydroepiandrosterone sulfate; p &lt; 0.01) and increases in estradiol (p &lt; 0.01). Basal cortisol levels and cortisol after ACTH stimulation were not changed significantly, remaining within the reference range. Increases in ACTH were observed only in the 3rd month (p &lt; 0.01). Initial levels of androgenic steroids were correlated inversely with their percentage decrease in successive samplings. Decreases in adrenal androgenic steroids were associated with an increase in steroid hormone-binding globulin. The side-effects of treatment, although not severe, caused some discomfort and led to a high drop-out rate (30%). Our results suggest that low doses of ketoconazole (400 mg\/day) are an alternative therapy for non-tumoral hyperandrogenism, although the bothersome side-effects, which require close monitoring and maximal patient compliance, make this treatment advisable only in selected patients.<\/jats:p>\n        <jats:p>Manuel Mu\u00f1oz-Torres, Plaza Isabel la Cat\u00f3lica no. 2, E-18009, Granada, Spain<\/jats:p>","DOI":"10.1530\/eje.0.1300333","type":"journal-article","created":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T21:19:42Z","timestamp":1229375982000},"page":"333-338","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":21,"title":["Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism"],"prefix":"10.1093","volume":"130","author":[{"given":"Antonio J","family":"Vidal-Puig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mu\u00f1oz-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"J\u00f3dar-Gimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos J","family":"Garc\u00eda-Calvente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda E","family":"Ruiz-Requena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Escobar-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/130\/4\/eje_130_4_003.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/130\/4\/eje_130_4_003.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:18:40Z","timestamp":1676391520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/130\/4\/333\/6754957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,4]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/eje.0.1300333","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,4]]}}}